Does Harvard Pilgrim Health Care Cover Eliquis?

How Harvard Pilgrim Lists Eliquis on Its Formulary

Harvard Pilgrim Health Care, now operating under the Point32Health umbrella after its 2021 merger with Tufts Health Plan, maintains a tiered prescription drug formulary that includes Eliquis (apixaban) for most commercial and Medicare Advantage plans. The exact tier placement depends on the specific product you are enrolled in.

For the majority of Harvard Pilgrim commercial plans, Eliquis sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). This distinction matters because it directly affects your out-of-pocket cost. A Tier 2 placement typically carries a copay between $35 and $50 per 30-day supply, while Tier 3 placement can push that to $60 to $90. Harvard Pilgrim updates its formulary annually, and mid-year changes are possible with advance notice to members. You can verify your plan's current formulary by logging into the Point32Health member portal or calling the number on the back of your insurance card.

Eliquis earned its formulary position based on strong clinical evidence. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke and systemic embolism by 21% compared to warfarin in patients with nonvalvular atrial fibrillation, with a 31% reduction in major bleeding [1]. These outcomes made apixaban a preferred direct oral anticoagulant (DOAC) across most U.S. insurance formularies.

Prior Authorization and Step Therapy Requirements

Most Harvard Pilgrim plans do not require prior authorization for Eliquis when prescribed for FDA-approved indications. These include reduction of stroke risk in nonvalvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT/PE, and DVT prophylaxis after hip or knee replacement surgery.

However, some plan designs may impose step therapy protocols. Step therapy means your insurer wants documentation that you tried a lower-cost alternative (usually warfarin) before approving the more expensive option. The 2019 AHA/ACC/HRS Focused Update recommends DOACs over warfarin for most patients with nonvalvular AFib, which gives your prescriber solid ground to request a step therapy override [2].

If your Harvard Pilgrim plan does require prior authorization for any reason, your physician's office submits the request. Approval turnaround is typically 24 to 72 hours for standard requests and under 24 hours for urgent cases. Denials can be appealed, and Harvard Pilgrim must respond to first-level appeals within 30 days for commercial plans or 7 days for Medicare Advantage expedited reviews.

Your prescriber should include the specific diagnosis code, any contraindications to warfarin (such as labile INR, dietary interactions, or difficulty accessing INR monitoring), and relevant clinical trial data supporting DOAC use. The AMPLIFY trial showed apixaban was noninferior to standard enoxaparin/warfarin therapy for acute VTE treatment while causing 69% less major bleeding (0.6% vs. 1.8%, P<0.001) [3].

What You Will Actually Pay for Eliquis

The retail price of Eliquis without insurance averages $550 to $620 for a 30-day supply of 60 tablets (5 mg twice daily). With Harvard Pilgrim coverage, your cost drops significantly, but the exact amount depends on several variables.

Commercial HMO/PPO plans: Expect copays of $35 to $90 per month depending on tier placement. Plans with coinsurance instead of flat copays may charge 20% to 40% of the negotiated drug cost, which could mean $80 to $150 per fill before any manufacturer discount.

Harvard Pilgrim Medicare Advantage plans: Medicare Part D formulary rules apply. Eliquis typically falls on Tier 3 (preferred brand) in Medicare plans. During the initial coverage phase, copays range from $42 to $100. Once you enter the coverage gap (the "donut hole"), the Inflation Reduction Act caps out-of-pocket insulin and certain drug costs, and the $2,000 annual out-of-pocket maximum for Part D (effective since 2025) means your total yearly Eliquis spend will not exceed that threshold [4].

Bristol-Myers Squibb copay card: Commercially insured patients (not Medicare, Medicaid, or other federal programs) can enroll in the Eliquis copay savings program. This card can reduce your copay to as low as $10 per month, with annual savings up to $6,400. The program renews each calendar year. According to the FDA-approved prescribing information for Eliquis, the recommended dose is 5 mg twice daily for most AFib patients, with a reduced 2.5 mg twice daily dose for patients meeting at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [5].

Preferred pharmacy networks: Harvard Pilgrim contracts with specific pharmacy chains for lower negotiated rates. Using CVS, Walgreens, or other in-network pharmacies typically results in lower copays than out-of-network fills. Mail-order pharmacy options through Point32Health may offer 90-day supplies at a reduced per-day cost.

Eliquis vs. Other Anticoagulants Covered by Harvard Pilgrim

Harvard Pilgrim's formulary includes several anticoagulant options beyond Eliquis. Understanding how they compare helps you and your prescriber make an informed choice if cost becomes a barrier.

Warfarin (generic): Tier 1, typically $4 to $15 per month. Warfarin requires regular INR blood monitoring (usually every 2 to 4 weeks), has numerous food and drug interactions, and carries a higher intracranial hemorrhage risk than DOACs. The ARISTOTLE trial found apixaban reduced intracranial hemorrhage by 58% compared to warfarin (0.33% vs. 0.80% per year) [1].

Xarelto (rivarelbaan): Often Tier 2 or Tier 3, with similar copays to Eliquis. Xarelto offers once-daily dosing for AFib but showed higher GI bleeding rates than warfarin in the ROCKET AF trial (N=14,264) [6]. Apixaban did not increase GI bleeding versus warfarin in ARISTOTLE, which is one reason many formulary committees give Eliquis a favorable position.

Savaysa (edoxaban): Less commonly prescribed and sometimes placed on higher tiers. The ENGAGE AF-TIMI 48 trial (N=21,105) showed edoxaban 60 mg daily was noninferior to warfarin for stroke prevention, with 20% less major bleeding [7].

Pradaxa (dabigatran): Typically Tier 2 or Tier 3. The RE-LY trial (N=18,113) demonstrated that dabigatran 150 mg twice daily reduced stroke by 34% versus warfarin but with similar major bleeding rates [8]. Pradaxa has a specific reversal agent (idarucizumab), as does Eliquis/Xarelto (andexanet alfa).

A 2022 network meta-analysis published in the European Heart Journal concluded that apixaban had the most favorable bleeding profile among all DOACs while maintaining strong efficacy for stroke prevention [9]. Dr. Elaine Hylek, professor of medicine at Boston University, has stated: "Apixaban has consistently shown the best balance of efficacy and safety across major randomized trials, which is why it became the most prescribed anticoagulant in the United States."

How to Confirm Your Specific Coverage

Formulary details change. The steps below will give you the most current information for your Harvard Pilgrim plan.

Step 1: Check the online formulary. Visit the Point32Health member portal and search for "apixaban" or "Eliquis" in the drug lookup tool. This shows your plan's tier, any restrictions, and preferred pharmacies.

Step 2: Call member services. The phone number on the back of your Harvard Pilgrim card connects you to a benefits specialist who can confirm your copay, any prior authorization requirements, and whether mail-order is cheaper for your plan.

Step 3: Ask your pharmacist to run a test claim. Before your prescriber sends the prescription, your pharmacist can process a test adjudication to see exactly what your plan will charge. This takes about five minutes.

Step 4: Request a formulary exception if needed. If Eliquis is on a higher tier or requires step therapy on your plan, your physician can submit a formulary exception request. The 2023 ACC/AHA Guideline for Atrial Fibrillation gives DOACs a Class I recommendation (Level of Evidence A) over warfarin for eligible patients with AFib, which supports exception requests [10].

Harvard Pilgrim must respond to exception requests within 72 hours for standard cases and 24 hours for expedited reviews. If denied, you have the right to an external independent review.

Medicare Advantage Considerations for Harvard Pilgrim Members

Harvard Pilgrim offers Medicare Advantage plans in Massachusetts, New Hampshire, Maine, and Connecticut through Point32Health. These plans follow CMS Part D formulary guidelines, which differ from commercial plan rules in several important ways.

The Inflation Reduction Act restructured Medicare Part D cost-sharing starting in 2025. The annual out-of-pocket cap of $2,000 means that even if Eliquis is on a higher tier, your total yearly drug spending is limited [4]. For a patient taking Eliquis 5 mg twice daily at a Tier 3 copay of $47 per fill, the annual cost would be $564, well within the cap. Patients on multiple expensive medications benefit even more from this ceiling.

Medicare Advantage plans cannot impose prior authorization requirements that are more restrictive than Original Medicare's coverage determinations. Since CMS recognizes DOACs as medically necessary for approved indications, Harvard Pilgrim's Medicare Advantage plans generally cover Eliquis without prior authorization for AFib stroke prevention and VTE treatment.

The CMS Medicare Part D prescriber utilization data shows apixaban was the single most prescribed anticoagulant among Medicare beneficiaries in 2024, with over 10 million Part D claims filled [4]. This high utilization reflects both clinical guideline support and broad formulary inclusion across Medicare plans.

Low-income subsidy (LIS) or "Extra Help" programs can further reduce Eliquis costs for qualifying Medicare members. LIS-eligible patients pay no more than $4.50 (generic) or $11.20 (brand) per prescription in 2026. Since no generic apixaban exists yet, LIS patients would pay the brand copay of $11.20 for Eliquis.

What to Do If Harvard Pilgrim Denies Eliquis Coverage

A denial does not end the conversation. The appeals process is structured and has defined timelines that work in the patient's favor.

Internal appeal: File within 180 days of the denial for commercial plans or 60 days for Medicare Advantage. Include your prescriber's letter of medical necessity, relevant clinical trial data, documentation of any adverse reactions to alternatives (warfarin, other DOACs), and the applicable guideline recommendation. The American College of Cardiology notes that DOACs are preferred over warfarin for most AFib patients without moderate-to-severe mitral stenosis or a mechanical heart valve [10].

External review: If the internal appeal is denied, Massachusetts and New Hampshire (Harvard Pilgrim's primary service areas) allow external independent medical review. An independent physician reviewer evaluates whether the denial was clinically appropriate. Massachusetts General Law Chapter 176O Section 14 governs this process.

Manufacturer patient assistance: Bristol-Myers Squibb and Pfizer (co-marketers of Eliquis) offer a patient assistance program for uninsured or underinsured patients. Eligible patients receive Eliquis at no cost. Income thresholds typically apply (usually at or below 300% of the federal poverty level).

Pharmacy discount programs: GoodRx, RxAssist, and NeedyMeds may offer coupons that reduce the cash price to $350 to $480 per month, which is still expensive but lower than the $550 to $620 retail price.

Generic Apixaban: Timeline and Insurance Implications

As of May 2026, no FDA-approved generic version of apixaban is available in the United States. Bristol-Myers Squibb and Pfizer hold composition-of-matter and formulation patents on Eliquis. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA, and patent litigation settlements suggest potential generic entry in late 2026 or 2027 [5].

When generic apixaban does reach the market, Harvard Pilgrim will almost certainly move it to Tier 1 (generic) with copays of $5 to $20 per month. The plan may also implement mandatory generic substitution, requiring pharmacists to dispense the generic unless the prescriber writes "brand medically necessary." This pattern followed the genericization of other blockbuster cardiovascular drugs. When generic atorvastatin (Lipitor) became available in 2011, commercial plan copays dropped from $40 to $50 per month to $4 to $10 within the first year.

For now, the combination of Harvard Pilgrim formulary coverage and the manufacturer copay card remains the most cost-effective path for commercially insured patients. Dr. Robert Harrington, chair of the Department of Medicine at Stanford University and past president of the American Heart Association, has stated: "Access to DOACs should not be limited by cost barriers, given their proven superiority over warfarin for bleeding safety in the majority of atrial fibrillation patients."

Patients nearing the anticipated generic launch date should discuss with their prescriber whether short-term use of a lower-cost alternative (if clinically appropriate) could bridge the gap, though switching anticoagulants carries its own risks and should only be done under medical supervision. The ARISTOPHANES study, a large real-world analysis of over 430,000 patients, confirmed that apixaban was associated with lower rates of stroke, major bleeding, and all-cause mortality compared to rivaroxaban and dabigatran in routine clinical practice [11].